News | July 02, 2024
Abbott and YRGCARE inaugurate new outreach centers in India
Offering testing, treatment and support to help stop the spread of HIV and other infectious diseases
Offering testing, treatment and support to help stop the spread of HIV and other infectious diseases
The launch of Cefepime-Enmetazobactam marks a significant milestone for India's pharmaceutical industry in fight against AMR
Innovative technology represents a breakthrough scientific achievement for highly contagious respiratory disease
Over 13 million US adults aged 50-59 years have a medical condition that increases their risk of severe RSV outcomes
The transaction aligns with Lupin's strategy to grow its global presence in Specialty areas
DCGI has also granted permission to manufacture and market FDF of Cefepime and Enmetazobactam as a dry powder injectable
mRESVIA is Moderna's second approved product and the only RSV vaccine available in single-dose pre-filled syringes
SUPERNOVA is a large Phase III global trial providing the only efficacy data in immunocompromised patients
First-quarter 2024 revenues totaled $14.9 billion, a decrease of $3.6 billion, or 20%, compared to the prior-year quarter
Sales reflect continued strong growth in oncology and vaccines
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
